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INTRODUCTION
Migraine is a debilitating disorder, characterized by severe headaches contributing to a
poor quality of life. Approximately 14% of Americans are afflicted with migraine headaches.
Migraine headache is described as unilateral pulsating pain with or without aura; it can have
associated photophobia, phonophobia, nausea, vomiting, and inability to carry on with daily
activities during an acute attack. People with migraine headaches often miss days from work and
important family events. It is the fifth most common reason for emergency department visits and
contributes to significant economic burden. Patients with episodic migraine often convert to
chronic migraine, which is defined as greater than 15 migraine days per month for three
consecutive months.1 In addition to current acute relief medications such as triptans and nonsteroidal anti-inflammatory drug (NSAIDS), it is imperative to start prophylactic medication
early.
Chronic migraine is a complex disorder that is difficult to manage and would benefit
from a multimodal approach. Lifestyle modifications and concomitant use of prophylactic
medications are key in migraine prevention. Patients should keep a headache diary to help
identify migraine triggers. Avoiding triggers and adapting the following recommendations are
crucial: adequate sleep, stress relaxation techniques, adequate hydration, regular exercise, timely
eating regular meals, limiting caffeine and other foods that trigger acute migraines. In addition to
lifestyle modifications the careful consideration of prophylactic medication is warranted under
the following circumstances: greater than 15 headache days per month, acute medication overuse
(greater than 8 days), and failure of acute medications to resolve the headache. Current
recommendations for chronic migraine prophylaxis are to start patients on a low dose nonselective beta blocker such as propranolol. Even though beta blockers are the preferred treatment
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other medications such as tricyclic anti-depressants, anti-epileptic drugs, and onabotulinum toxin
(Botox) are commonly used due to a high number of patients who that are refractory to first line
treatment.1 The following is a review of medical literature on patients with chronic migraine and
the comparison of topiramate with Botox for migraine prophylaxis, and the effect on the number
of headaches per month, over a 12-week period.
This is a review of two prophylactic medications for chronic migraine prophylaxis, Botox
and topiramate. Three articles were selected that reviewed the efficacy of topiramate and
regarding the effectiveness of Botox. These articles measured quality of life through a Migraine
Specific Quality of Life Questionnaire. Inclusion criteria for choosing these articles is as
follows; articles must be published within the last 15 years, focus must be adults excluding
pediatric populations, primary focus of the articles is chronic migraines, research studies must
follow patients for at least 12 weeks.
TOPIRMATE EFFECTIVENESS
Topiramate is an Anti-epileptic medication that has been proven to show improvement in
chronic migraine symptoms. The following research studies evaluated topiramate efficacy in
chronic migraine prophylaxis, both studies found that it significantly reduced the severity and
number of headaches per month.
In a randomized double-blind trial conducted by Silberstein et all, topiramate was shown
to be an efficacious prophylactic agent for chronic migraine prevention when compared to
placebo. The study evaluated the efficacy of topiramate, in a trial that extended over the course
of 16 weeks and had a total of 306 patients. Participants were divided into two groups treatment
and placebo. The treatment group was titrated up to topiramate 100mg daily. The study
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concluded that topiramate 100mg daily significantly reduced the number of migraine days when
compared to the placebo group.2 In the treatment group patients reported mild to moderate side
effects ranging from paresthesia, upper respiratory infection, and fatigue. The placebo group also
reported similar side effects, the most common were fatigue, nausea, and upper respiratory
infection. The following study had similar findings in a slightly different chronic migraine
population group, one that overused abortive treatments such as triptans and NSAIDS.
Similarly, in the following study topiramate was found to be efficacious in the treatment
of those with an average of 20 migraine days per month. The study was a small 59 person
randomized double-blind placebo-controlled trial. At baseline 78% of the participants were
overusing acute medication. Medication overuse is defined as the use of abortive treatment such
as triptans or NSAIDS greater than eight days per month. Medication overuse is a major
contributor to rebound headaches thus, adding to the number of headache days per month in
these patients.3 All ongoing migraine prophylactic medications in the antiepileptic medication
class were discontinued. Other prophylactic medications were continued if the patient continued
to have greater than 15 migraine days per month.
Topiramate reduced the number of migraines in those with acute medication overuse.
Topiramate was titrated up to a dose of 100mg over the course of several weeks. At the
completion of the 16-week trial, topiramate statistically significantly reduced the number of
migraines per month when compared to the placebo, which increased by one. The most common
side effect noted in both the treatment and control group was paresthesia which occurred in about
half of the topiramate group and less than 10% in the placebo group. The Migraine Disability
Assessment (MIDAS) showed an improvement in quality of life with the use of topiramate;
however, these results were not statistically significant, due to lack of power with a small sample
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size.3 Overall, topiramate is tolerated and proven to be an effective means of migraine
prophylaxis, which significantly reduces the quantity and severity of migraine headaches per
month.
BOTOX EFFECTIVENESS
Botox is a medication that is injected into the muscles and leads to temporary muscle
paralysis. Although the physiology behind how it prevents migraine headaches is not completely
understood, the following studies demonstrates it is as an effective means of chronic migraine
prophylaxis, in patients that have failed oral therapies. The first article was a review of two large
phase III research studies that evaluated Botox as a prophylactic medication for chronic migraine
headaches.4 Both studies were randomized controlled trials that evaluated a total of 1384
participants. Patients received Botox injections every three months for a total of two years. The
studies had similar findings; Botox is efficacious in decreasing the quantity of migraine
headaches. The studies also assessed quality of life through several questionnaires. Botox
improved quality of life in patients with chronic migraine and was generally tolerated. Patients
reported the following side effects neck pain, muscle weakness, and eye ptosis.4 A similar study
was done that followed patients for one year had similar findings.
This was a long-term study that followed patients for a year and was divided into a
double-blind trial then opened as a non-blinded trial. After the blinded portion of the study
researchers found that Botox decreased the number of headaches per month and the severity of
symptoms when compared to placebo. During the open phase of the trial all patients received
Botox injections every three months. At one year the study concluded that patients in the early
treatment group were found to have a greater than 50% reduction in migraine days per month.4
Botox also showed an improvement in quality of life as measured by the quality of life
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questionnaires. Another long-term trial had similar findings such as decreased number of
headache days by greater than 50% per month.
A similar trial was conducted to evaluate the effectiveness of Botox as prophylaxis for
chronic migraine. This was a long-term study that followed patients for two years. This study
had a total of 716 participants all of which received Botox injections every three months, for the
course of the study. Upon completion of the study, patients had a statistically significant
reduction of greater than 50% in migraine headaches per month.5 The most common side effect
reported by patients was neck pain. Quality of life was evaluated using questionnaires throughout
the study. Patients had a significant improvement in quality of life with the use of Botox due to
the significant reduction in pain and headaches days per month. Now that topiramate and Botox
have been found to be effective it is important to compare them to determine which is the
superior option. One key limitation of this study was that it was an open-label trial, researchers
reported that it would be unethical to have participants on a placebo for two years.
COMPARISION OF BOTOX AND TOPIRAMATE
In previous studies, when Botox and topiramate were compared to placebos, they both
prove to be an effective means of chronic migraine prophylaxis. A small double-blind
randomized pilot study has been conducted, to determine which of these two prophylactic
medications is superior. This study was conducted for 6 months and concluded that both
treatment groups saw a reduction in quantity of headaches per month and improvement in quality
of life. No statistical significance was found between the two medications. Both medications are
equally effective, and either should be used for chronic migraine prophylaxis.6
DISCUSSION
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In evaluation of the efficacy between Botox and topiramate for prophylaxis of chronic
migraine, the conclusion was that both medications were of equal effectiveness. Individual
studies with topiramate and Botox had similar findings that both medications substantially
reduced the number of migraine days per month and improved quality of life. Only one trial has
been conducted comparing topiramate and Botox as a treatment for prevention of chronic
migraine; statistical significance was not found to favor one drug or the other due to small
sample size. More research studies need to be conducted with a larger population to determine
which is the best treatment option. It is important to also compare treatment options by
evaluating the side effect profile, route of administration, and cost to determine the best
treatment option for patients. Patients have different responses to medication, and one treatment
may work better for one person and the same treatment may not work well for another patient.
With chronic migraine prophylaxis it is often a process of trial and error of various prophylactic
meds until the best treatment is found for that individual patient. During this time, it is also
important to continue lifestyle changes in addition to pharmacological treatment.
Although, neither topiramate or Botox were found to be a superior prophylactic treatment
in reducing migraine days, practitioners may soon find a better choice. An-Calcitonin generelated peptide (CGRP) monoclonal antibodies are a new class of medication that has been found
to reduce chronic migraine headaches. This new class of medication is now FDA approved for
prevention of chronic migraine. CGRP antibodies medications such as Eptinezumab work by
blocking Calcitonin gene related peptides that are released by the trigeminal nerve during an
acute migraine. In phase three clinical trials, this class of medication was found to significantly
reduce migraine days by about 15 migraine days per month. Common adverse effects noted in
the trial are injection site reaction and pain.7 When choosing prophylactic medication for patients
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with chronic migraine, it is important to consider this new class of medication as a treatment
option.
CONCLUSION
Chronic migraine headaches are a complex disorder to manage. It is important for
practitioners to consider prophylactic medication in patients with chronic migraine, those who
have failed acute treatments, and those with acute medication overuse. Medication overuse as an
indication for migraine prophylaxis because this can quickly progress from episodic migraine
headache to chronic migraine headaches.6 Patients were found to have an improvement in quality
of life with the use of either topiramate or Botox as prophylactic agents. Practitioners can also
consider the use of CGRP antibodies as prophylaxis for their patients. It is important to also
consider side effect profiles. Careful consideration needs to be done when using a new
medication with unknown long-term side effects. Overall, these are all suitable options for the
prevention of chronic migraine and should be used in conjunction with lifestyle modifications.
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